SAM
CPRX

Smartleaf Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Smartleaf Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$14K Sell
589
-1,175
-67% -$28K ﹤0.01% 2151
2025
Q4 		$41.1K Buy
1,764
+630
+56% +$14K ﹤0.01% 1649
2025
Q3 		$22.2K Buy
1,134
+111
+11% +$2.28K ﹤0.01% 1779
2025
Q2 		$22.3K Buy
1,023
+246
+32% +$5.81K ﹤0.01% 1504
2025
Q1 		$19.2K Sell
777
-68
-8% -$1.53K ﹤0.01% 1623
2024
Q4 		$17.8K Buy
845
+559
+195% +$12K ﹤0.01% 1711
2024
Q3 		$5.59K Buy
286
+57
+25% +$1.06K ﹤0.01% 2072
2024
Q2 		$3.44K Buy
+229
New +$3.56K ﹤0.01% 1985

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Smartleaf Asset Management's CPRX Position: Q1 2026 in Review

Smartleaf Asset Management reduced its Catalyst Pharmaceutical (CPRX) stake by 67% in Q1 2026, selling an estimated $28K and leaving 589 shares worth $14K. The position accounts for ﹤0.01% of the portfolio, ranked #2151.

Smartleaf Asset Management first reported a position in CPRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $41.1K in Q4 2025. 380 funds tracked by Wall St. Rank hold CPRX as of Q1 2026.

  • Smartleaf Asset Management held 589 shares of Catalyst Pharmaceutical worth $14K as of Q1 2026.
  • Smartleaf Asset Management sold 1,175 Catalyst Pharmaceutical shares in Q1 2026, an estimated $28K.
  • Catalyst Pharmaceutical made up ﹤0.01% of Smartleaf Asset Management's portfolio in Q1 2026, its #2151 holding.
  • Smartleaf Asset Management first reported a position in Catalyst Pharmaceutical in Q2 2024 and has held it in 8 quarters since.
  • Smartleaf Asset Management's Catalyst Pharmaceutical position peaked at $41.1K in Q4 2025.
  • 380 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q1 2026.

Based on Smartleaf Asset Management's 13F filing for Q1 2026, filed 15 May 2026.